Answers are grounded in this paper and cite their sources.
Background The World Health Organization has identified Marburg as an emerging virus requiring urgent vaccine research and development, particularly relevant due to its recent emergence in Ghana. Here we report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type-3 (cAd3) vectored vaccine encoding a wild-type Marburg Angola glycoprotein (cAd3-Marburg) in healthy adults. Methods We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18–50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 or 1 × 1011 particle units (pu). Primary safety endpoints included reactogenicity assessed for the first 7 days and all adverse events assessed for 28 days after vaccination. Secondary immunogenicity endpoints were assessment of binding antibody responses and T-cell responses against the Marburg virus glycoprotein insert, and assessment of neutralising antibody responses against the cAd3 vector 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT03475056. Findings Between Oct 9, 2018, and Jan 31, 2019, 40 healthy adults were enrolled and assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 pu (n=20) or 1 × 1011 pu (n=20). The cAd3-Marburg vaccine was safe, well tolerated, and immunogenic. All enrolled participants received cAd3-Marburg vaccine, with 37 (93%) participants completing follow-up visits; two (5%) participants moved from the area and one (3%) was lost to follow-up. No Serious Adverse Events (SAEs) related to vaccination occurred. Mild to moderate reactogenicity was observed following vaccination, with symptoms of injection site pain and tenderness (n=27/40, 68%), malaise (n=18/40, 45%), headache (n=17/40, 43%), and myalgia (n=14/40, 35%) most commonly reported. Glycoprotein-specific antibodies were induced in 38 (95%) of 40 participants 4 weeks after vaccination, with geometric mean titres of 421 [95% CI 209–846] in the 1 × 1010 pu group and 545 [276–1078] in the 1 × 1011 pu group, and remained significantly elevated at 48 weeks compared with baseline titres (39 [95% CI 13–119] in the 1 ×1010 pu group and 27 [95–156] in the 1 ×1011 pu group; both p<0·0001). T-cell responses to the GP insert and neutralizing responses against the cAd3 vector were also increased at four weeks after vaccination. Interpretation This first-in-human trial demonstrated this novel cAd3-Marburg vaccine is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. Ninety-five percent of participants produced a GP-specific antibody response after a single vaccination, that remained in 70% of participants at 48 weeks. These findings represent a critical step in development of a vaccine for emergency deployment against a re-emerging pathogen that has recently expanded its reach to new regions.
No takes yet. Share an insight, caveat, or question.
Hamer et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: